半乳凝集素-3对心力衰竭患者的诊断及评估作用

doi:10.3969/j.issn.1002-1949.2018.01.009

Chinese Journal of Critical Care Medicine

2018, Vol. 38

Issue (1): 37-40 DOI: 10.3969/j.issn.1002-1949.2018.01.009

Diagnosis and evaluation of Galectin-3 in patients with heart failure

Zhang Bo, Zhang Yan-hong, Deng Yang

Emergency Internal Medicine, Jilin Provincial People′s Hospital, Changchun 130021, China

Abstract
Figure/Table
References (14)
Related Citation (15)

Download: PDF (424 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the diagnosis and evaluation of Galectin-3 in patients with heart failure. Methods: Forty patients with heart failure were included in this study. Before and after treatment, Galectin-3, BNP were measured. The relationship between Ga-3 and BNP was analyzed. One week after treatment, echocardiography was performed and EF, LVEDD were measured. The relationship between Ga-3, BNP and EF, LVEDD was analyzed. The treatment effect was divided into effective group and ineffective group. The levels of Ga-3, BNP of the two groups were compared. Grouping according to cardiac function, correlation between Ga-3 and cardiac function classification was analyzed. The patients were followed up for 3 months to record the information about rehospitalization and death. Results: ①Correlation analysis showed that the serum levels of Ga-3 and BNP, LVEDD, cardiac functional grading had a positive correlation; Correlation analysis showed that the serum levels of Ga-3, BNP and EF had a negative correlation. ②The effective rate of BNP in treatment group was significantly lower than that before treatment (P<0.05); No significant decrease was seen in Ga-3 (P>0.05). After treatment, the Ga-3 and BNP of the treated group were significantly higher than those before treatment (P<0.05). ③The patients were followed up for 3 months, the level of Ga-3, BNP in the adverse event group was significantly higher than that in the group without adverse cardiac events. Conclusion: In patients with heart failure, correlation analysis shows that the serum levels of Ga-3 and cardiac hypofunction, myocardial remodeling have a negative correlation. It can assess the prognosis in patients with heart failure. It can be used as a new biomarker for diagnosis, treatment, risk stratification and evaluation of prognosis in patients with heart failure.

Received: 25 August 2017

About author:: Zhang Bo, E-mail: zhb20014@163.com

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhang Bo
	Zhang Yan-hong
	Deng Yang

Cite this article:

Zhang Bo,Zhang Yan-hong,Deng Yang. Diagnosis and evaluation of Galectin-3 in patients with heart failure[J]. Chinese Journal of Critical Care Medicine, 2018, 38(1): 37-40.

URL:

http://www.cnemergency.org.cn/EN/10.3969/j.issn.1002-1949.2018.01.009 OR http://www.cnemergency.org.cn/EN/Y2018/V38/I1/37

［1］何东升，柳云恩，赵科研，等.半乳糖凝集素3与心力衰竭［J］．中华老年心脑血管病杂志， 2014, 16（8）：875-877. ［2］Yu L， Ruifrok WP， Meissner M， et al． Genetic and pharmacological inhibition of galectin-3 prcvents cardiac remodeling by interfering with myocardialfibrogenesis［J］． CircHeartFail， 2013， 6(1)：107-117． ［3］Gruson D, Ko G. Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases［J］. Clin Biochem, 2012, 45(10-11): 719-726． ［4］Lok DJ, Lok SI, Bruggink-Andre de la Porte PW, et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure ［J］. Clin Res Cardiol, 2013, 102(2):103-110. ［5］McMurray JJ, Adamopoulos S, Anker SD, et al. Task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology［J］. Eur J Heart Fail, 2012, 14(8):803-869.  ［6］Gerdes AM, Ojamaa K. Thyroid hormone and cardioprotection ［J］. Compr Physiol, 2016, 6（3）: 1199-1219.［7］Zhang R, Zhang Y, An T, et al. Prognostic value of sST2 and galectin- 3 for death relative to renal function in patients hospitalized for heart failure［J］. Biomark Med, 2015, 9 (5): 433- 441. ［8］van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelinfortheevaluationofpatientswithacuteheart failure ［J］. J Am Coll Cardiol, 2006, 48（6）: 1217-1224 ． ［9］秦月，仲琳，杨军.Galectin-3 评估冠心病预后的临床价值［J］.国际心血管病杂志， 2015, 42（3）：207-211. ［10］Lok DJ , Van Der Meer P, de la PortePW, et al. Prognostic value of galectin-3, anovel marker of fibrosis in patients with chronic heart failure:data fromthe DEAL-HF study［J］.Clin Res Cardiol, 2010, 99(5):323-328. ［11］Chen K, Jiang RJ, Wang CQ, et al. Predictive value of plasma galectin-3 in patients with chronic heart failure［J］. Eur Rev Med Pharmacol Sci, 2013, 17(8): 1005-1011. ［12］Yin QS, Shi B , Dong L, et al. Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure［J］. J Geriatr Cardiol, 2014, 11(1): 79-82. ［13］Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality inpatients with acutely decompensated heart failure［J］. Eur J Heart Fail, 2010, 12: 826-832. ［14］Lainscak M, Coletta AP, Sherwi N, et al. Clinical trials update from the Heart Failure Society of America Meeting 2009:FAST,IMPROVE-HF,COACH galectin-3 substudy, HF-ACTION nuclear substudy,DAD-HF, and MARVEL-1［J］. Eur J Heart Fail, 2010, 12（2）:193-196.